Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129203 | 0.78 | CDK4 (0.34) | MAPK14SYKAURKACYP1A2CYP3A4 | |
| SCHEMBL16129099 | 0.75 | KDR (0.37) | MAPK14SYKCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16129057 | 0.72 | AURKA (0.39) | SYKAURKACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL22950960 | 0.72 | MAPK14 (0.40) | MAPK14PPARGPPARASYKAURKA | |
| SCHEMBL27773155 | 0.72 | MAPK14 (0.39) | MAPK14PPARGPPARASYKAURKA | |
| SCHEMBL5388892 | 0.70 | MAPK14 (0.46) | MAPK14SYKLCKALDH1A1 | |
| SCHEMBL15489512 | 0.69 | MAPK10 (0.57) | MAPK14SYK | |
| SCHEMBL17260953 | 0.68 | TNIK (0.43) | MAPK14SYKCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3631100 | 0.68 | MAPK14 (0.45) | MAPK14SYKLCK | |
| SCHEMBL23887607 | 0.67 | SYK (0.42) | SYKAURKALCKALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2014151871-A9 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014151871-A2 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MAPK14 581/4885PPARG 2544/4885PPARA 2468/4885 |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MAPK14 546/4885PPARG 2505/4885PPARA 2755/4885 |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MAPK14 581/4885PPARG 2544/4885PPARA 2468/4885 |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | ALK, JAK2, JAK1 | MAPK14 581/4885PPARG 2544/4885PPARA 2468/4885 |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | ALK, JAK1, JAK2 | MAPK14 436/4885PPARG 2809/4885PPARA 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.